tbuckley/cabot-search huggingface dataset:
Enfermedades prevenibles por la vacunación: la vigilancia regional puede contribuir a mejorar la comparación de datos entre países
Authors: J C Desenclos
Journal: Eurosurveillance (2001)

La forma de practicar la vigilancia de una enfermedad en los paises europeos varia enormemente. Todos los estudios realizados hasta la fecha sobre este tema han llegado a la misma conclusion, vinculando la variacion reflejada entre paises a muchos factores, entre los cuales la organizacion de la atencion sanitaria juega un papel fundamental.
68Ga-DOTATATE Uptake in Ischemic Stroke
Authors: Émilie Vallée, Nancy Paquet, James Patrick Buteau, Éric Turcotte
Journal: Clinical Nuclear Medicine (2017)

A 76-year-old man known to have a pancreatic neuroendocrine tumor with hepatic and lymph nodes metastasis had a follow-up Ga-DOTATATE PET/CT before Lu-DOTATATE therapy. A new cerebral lesion expressing somatostatin receptors was discovered in the right temporal lobe, suggestive of an ischemic stroke territory. This was later confirmed from the hospital chart where an ischemic stroke was described a month ago.
US doctors voice concern over plans to raid public health fund to pay for children’s healthcare
Authors: Owen Dyer
Journal: BMJ (2017)

A US Republican bill to extend the popular Children’s Health Insurance Program will strip money from efforts to prevent infectious disease, lead poisoning, and opioid addiction, say public health advocates.

The Clinton era program known as CHIP—which for 20 years has insured millions of lower income US children—expired on 30 September, halting federal payments to states that administer the program. All states are currently continuing the program using unspent dollars from previous transfers, but these funds will run out in over 30 states by the end of spring 2018.

The Community Health and Medical Professionals Improve Our Nation (CHAMPION) Bill, sponsored by an Oregon Republican, Greg Walden, aims to restart CHIP …
The effects of LIPUS on ctDNA release in the medium of NSCLC cell lines
Authors: A. Perez, A.B. Di Stefano, M. Castiglia, M. Sorrentino, D. Matranga, F. Grisafi, C. Corso, G. Scoarughi, G. Barbato, N. Barraco, V. Calò, F. Di Piazza, D. Massihnia, A. Listì, L. Castellana, A.A. Guarini, L. Insalaco, E. Bronte, A. Russo
Journal: Annals of Oncology (2017)
Potentially inappropriate liver transplantation in the era of the “sickest first” policy – A search for the upper limits
Authors: Michael Linecker, Tanja Krones, Thomas Berg, Claus U. Niemann, Randolph H. Steadman, Philipp Dutkowski, Pierre-Alain Clavien, Ronald W. Busuttil, Robert D. Truog, Henrik Petrowsky
Journal: Journal of Hepatology (2017)
Controlo da rubéola em Itália
Authors: M L Ciofi Degli Atti, A Filia, M G Revello, W Buffolano, S Salmaso
Journal: Eurosurveillance (2004)

Em Italia, a vacinacao contra a rubeola esta recomendada desde 1972 para raparigas pre-adolescentes e desde o inicio dos anos noventas para todas as criancas no segundo ano de vida. Nao obstante, a cobertura em criancas dos 12 aos 24 meses de idade e subideal (ou seja, 56% em 1998, 78% em 2003), com amplas variacoes entre regioes.
Em consequencia, a rubeola ainda se encontra a circular no pais e, em 1996, a proporcao de mulheres entre os 15 e os 39 anos de idade suscepiveis a rubeola era g 5%. 
O sindrome da rubeola congenita (CRS) era de notificacao entre 1987 e 1991, com 8 a 76 casos notificados anualmente. Desde 1992, os dados nacionais de incidencia deixaram de estar disponiveis, mas relatos locais mostram que ainda ocorrem casos de CRS. 
Sao necessarias accoes de âmbito nacional, coordenadas e uniformes para controlar eficazmente o CRS. Por esta razao, foi lancado recentemente o Plano Nacional para a Eliminacao do Sarampo e da Rubeola Congenita. Este plano inclui estrategias que se destinam a aumentar a cobertura da vacinacao MMR na crianca e a implementar medidas especificas de controlo para o controlo da rubeola congenita, ou seja, melhorando a vacinacao de mulheres susceptiveis em idade reprodutora e reintroduzindo a vigilância nacional do CRS.
First line treatment with carboplatin-paclitaxel-bevacizumab in ovarian cancer: retrospective review of a single institute experience
Authors: A. Bologna, A. Garcia-Arias, L. Baldi, A. Berselli, M. Pagano, F. Zanelli, G. Bisagni, E. Gervasi, G. Stridi, B. Candida, A. Romagnani, R. Gnoni
Journal: Annals of Oncology (2017)
IMMU-66. IDO1 EXPRESSION STRATIFIES PATIENT SURVIVAL AND IS REGULATED BY TUMOR INFILTRATING T CELLS IN HUMAN GLIOBLASTOMA
Authors: Lijie Zhai, Erik Ladomersky, Kristen Lauing, Meijing Wu, Matthew Genet, Galina Gritsina, Balazs Gyorffy, Priscilla Brastianos, David Binder, Jeffrey Sosman, Francis Giles, C David James, Craig M Horbinski, Roger Stupp, Derek Wainwright
Journal: Neuro-Oncology (2017)

Indoleamine 2, 3 dioxygenase 1 (IDO1) mediates potent immunosuppression in multiple preclinical models of cancer. However, the basis for elevated IDO1 expression in human cancer, including the most common and malignant primary brain tumor in adults, glioblastoma (GBM), is poorly understood. The major objective of this study is to address this gap in our understanding of how IDO1 expression contributes to the biology of GBM, and whether its level of expression is a determinant of GBM patients’ outcome. Freshly resected human GBM, human T cell:GBM co-cultures, nu/nu, NOD-scid and humanized (NSG-SGM3-BLT) mice engrafted human GBM as well as the cancer genome atlas form the basis of our investigation. In situ hybridization for IDO1 revealed consistent transcript expression in all human GBM samples (n=172), whereas immunohistochemical IDO1 expression was highly variable. Multivariate analysis revealed that higher levels of IDO1 transcript predicted/correlated with shorter survival in the TCGA dataset (P=0.0076). IDO1 mRNA levels positively correlate with increased gene expression for markers of cytolytic and regulatory T cells, in addition to decreased patient survival. Humanized mice intracranially-engrafted with human GBM revealed an IFNγ-associated and T cell-mediated increase of intratumoral IDO1 expression. Our data demonstrate that high intratumoral IDO1 mRNA levels correlate with inferior GBM patient outcome; together with the positive correlation between increased IDO1 levels and infiltrating T cells suggests that IDO inhibition may have a key role in mediating immune response in GBM. Future immunotherapeutic efforts aiming to increase T cell-mediated immune response should consider combinatorial approaches that inhibit potential T cell-mediated IDO1 upregulation during therapy.
Caractérisation de l’écouvillonnage pour les analyses virologiques dans le réseau de surveillance par sentinelles en Espagne au cours de quatre saisons grippales pour la période 2002-2006
Authors: A Larrauri, S De Mateo, Spanish Influenza Sentinel Surveillance System
Journal: Eurosurveillance (2007)

Cette etude avait pour objectif de caracteriser le schema d’ecouvillonnage du reseau sentinelle de surveillance en Espagne (Spanish Influenza Sentinel Surveillance System, SISSS) et d’evaluer dans quelle mesure le systeme repond aux recommandations en cours d’elaboration de l’EISS (European Influenza Surveillance Scheme, Programme europeen de surveillance de la grippe).
JAK2-binding long noncoding RNA promotes breast cancer brain metastasis
Authors: Shouyu Wang, Ke Liang, Qingsong Hu, Ping Li, Jian Song, Yuedong Yang, Jun Yao, Lingegowda Selanere Mangala, Chunlai Li, Wenhao Yang, Peter K. Park, David H. Hawke, Jianwei Zhou, Yan Zhou, Weiya Xia, Mien-Chie Hung, Jeffrey R. Marks, Gary E. Gallick, Gabriel Lopez-Berestein, Elsa R. Flores, Anil K. Sood, Suyun Huang, Dihua Yu, Liuqing Yang, Chunru Lin
Journal: Journal of Clinical Investigation (2017)

Conventional therapies for breast cancer brain metastases (BCBMs) have been largely ineffective because of chemoresistance and impermeability of the blood-brain barrier. A comprehensive understanding of the underlying mechanism that allows breast cancer cells to infiltrate the brain is necessary to circumvent treatment resistance of BCBMs. Here, we determined that expression of a long noncoding RNA (lncRNA) that we have named lncRNA associated with BCBM (Lnc-BM) is prognostic of the progression of brain metastasis in breast cancer patients. In preclinical murine models, elevated Lnc-BM expression drove BCBM, while depletion of Lnc-BM with nanoparticle-encapsulated siRNAs effectively treated BCBM. Lnc-BM increased JAK2 kinase activity to mediate oncostatin M– and IL-6–triggered STAT3 phosphorylation. In breast cancer cells, Lnc-BM promoted STAT3-dependent expression of ICAM1 and CCL2, which mediated vascular co-option and recruitment of macrophages in the brain, respectively. Recruited macrophages in turn produced oncostatin M and IL-6, thereby further activating the Lnc-BM/JAK2/STAT3 pathway and enhancing BCBM. Collectively, our results show that Lnc-BM and JAK2 promote BCBMs by mediating communication between breast cancer cells and the brain microenvironment. Moreover, these results suggest targeting Lnc-BM as a potential strategy for fighting this difficult disease.
EXTH-62. TG02, A NOVEL TARGETING OF TRANSCRIPTION AND METABOLISM IN GLIOBLASTOMA
Authors: Yu-Ting Su, Robert Chen, Hua Song, Qi Zhang, Aiguo Li, Orieta Celiku, Kristan Meetze, Tom Estok, Dragan Maric, Zhengping Zhuang, Chunzhang Yang, Wei Zhang, Mark Gilbert, Jing Wu
Journal: Neuro-Oncology (2017)

Glioblastoma (GBM), a common malignant brain tumor, is highly resistant to most treatments, largely due to disease heterogeneity and resistance mechanisms. We investigated TG02, a multi-kinase inhibitor with established anti-tumor activities in hematologic malignancies, for a potential GBM therapy. We previously demonstrated that TG02 inhibited CDK9-mediated transcriptional regulation of anti-apoptotic proteins and induced Cytochrome c release, inducing cell apoptosis through Caspase-3 activation. Additionally, TG02 and Temozolomide (TMZ) demonstrated a synergistic anti-glioma effect in vivo and in vitro. A phosphorylation mimic form of CDK9 was overexpressed in GBM cell and cell viability was via cell counting. NADH dehydrogenase activity was measured to determine mitochondrial respiratory chain complex I activity. The glycolytic effects were measured by Seahorse assay and Western blotting of the key enzymes. Mitochondrial membrane potential change and apoptosis were measured by FACS with DiOC6, and Hoechst/PI staining, respectively. Pharmacodynamic studies were carried out using a syngeneic GBM mouse model. We demonstrated that overexpressed phosphorylation mimic form of CDK9 partially blocked TG02-induced cell death, suggesting that CDK9 mediates TG02-induced cytotoxicity. We demonstrated that TG02 caused mitochondrial dysfunction partially by reducing mitochondrial respiratory chain complex I activity. Additionally, TG02 inhibited glycolysis by downregulating key glycolytic regulators, including Hexokinase-2 (HK-2) and Pyruvate kinase M2 (PKM2), leading to ATP depletion. Combined treatment further enhanced ATP depletion, explaining the synergism between TG02 and TMZ. More importantly, TG02 did not cause mitochondrial damage and apoptosis in normal human astrocytes, suggesting a feasible therapeutic window for TG02. Furthermore, our pharmacodynamic studies confirmed that TG02 suppressed CDK9 activity in brain tumor tissues. TG02 has unique anti-glioma effects through transcriptional regulation of survival proteins, and reduction of cellular energy level in GBM cells. Our preclinical results have led to an ongoing Phase I//II clinical trial for patients with refractory GBM (NCT02942264).
PDTM-36. NEW THERAPEUTIC APPROACH FOR BRAINSTEM GLIOMA: INTRANASAL DELIVERY OF NANOLIPOSOMAL SN-38
Authors: Xingyao He, Peng Zhang, Nundia Louis, Hiroaki Katagi, Irina Balyasnikova, Craig Horbinski, Stewart Goldman, Rintaro Hashizume
Journal: Neuro-Oncology (2018)

Children with diffuse intrinsic pontine gliomas (DIPGs) die within 2 years after initial diagnosis. The infiltrative nature and anatomic location of DIPGs preclude surgical resection, and the blood-brain barrier (BBB) reduces the availability of systemically administered agents. New drug delivery approaches circumventing the BBB are greatly needed. Intranasal delivery (IND) is a practical, noninvasive method to deliver therapeutic agents into the brain along with the olfactory and trigeminal nerves pathway. With the advantages of reducing systemic side effects and convenient self-administration for patients, IND is an alternative to systemic and direct invasive drug deliveries. Human DIPG cell lines were treated with hydrophobic fluorophore (DiI)–labeledliposomes containing SN38 (LS-SN38). Cell viability was determined by MTS assay and intracellular localization was imaged by confocal microscopy. Mice bearing human brainstem gliomas were randomly assigned to 2 groups: empty liposomes (LS-empty) and LS-SN38, administrated IND for 3 weeks. Tumor growth and response to therapy were quantitatively measured by bioluminescence imaging, and efficacy was assessed by survival analysis. Ex vivo distribution of fluorescent liposomes were confirmed with fluorescent microscopy. Pharmacokinetics of LS-SN38 was determined in DIPG tumor by HPLC method. Intracellular fluorescence signals were detected at 30 minutes and peaked at 24 hours. LS-SN38 showed greater inhibition than LS-CPT11 of DIPG cell growth. IND of LS-SN38 showed significant reduction of growth rate and prolongation of survival in compared to control group. Ex vivo fluorescent signals were detected throughout different brain regions, indicates diffuse distribution in brainstem. Results from pharmacokinetics will be reported at the meeting.
OA 05.07 Efficacy and Updated Safety of Ceritinib (450 Mg or 600 Mg) with Low-Fat Meal vs 750 Mg Fasted in ALK+ Metastatic NSCLC
Authors: B.C. Cho, R. Obermannová, A. Bearz, D. Kim, S. Orlov, G. Borra, S. Kim, P.E. Postmus, S. Laurie, K. Park, S. Geater, A.C. Bettini, K. Osborne, V.Q. Passos, Z. Chen, R. Dziadziuszko
Journal: Journal of Thoracic Oncology (2017)
Tendencias en la enfermedad meningocócica por serogrupo C en la República de Irlanda
Authors: J Fogarty
Journal: Eurosurveillance (1997)

En noviembre de 1.994 se establecio en la Republica de Irlanda (RDI) un sistema nacional de vigilancia por laboratorio para la enfermedad meningococica. Cada mes, se remiten impresos de recogida de datos al nivel central, hayan o no habido casos, que contienen un conjunto minimo de datos (nombre, fecha de nacimiento, fecha del aislamiento, lugar del aislamiento, serogrupo, serotipo y subtipo si se dispone de esta informacion, asi como estado de supervivencia).
The pre-emptive screening of multiple polymorphisms in gene-encoding dihydropyrimidine dehydrogenase (DPD) improve prevention of toxicity on patients candidate for fluoropyrimidine based-chemotherapy. An experience of the Reggio Emilia Cancer Center
Authors: F. Iachetta, A. Damato, C. Bonelli, A. Romagnani, M. Banzi, D. Nicoli, E. Farnetti, B. Casali, C. Pinto
Journal: Annals of Oncology (2017)
Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial
Authors: David L Kendler, Fernando Marin, Cristiano A F Zerbini, Luis A Russo, Susan L Greenspan, Vit Zikan, Alicia Bagur, Jorge Malouf-Sierra, Péter Lakatos, Astrid Fahrleitner-Pammer, Eric Lespessailles, Salvatore Minisola, Jean Jacques Body, Piet Geusens, Rüdiger Möricke, Pedro López-Romero
Journal: The Lancet (2017)
NIMG-40. USE OF DYNAMIC CONTRAST ENHANCED MRI IN PREDICTING RESPONSE TO IMMUNOTHERAPY IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA
Authors: Kathryn Nevel, Mark Schreyer, Katherine Panageas, Robert J Young, Mariza Daras
Journal: Neuro-Oncology (2017)

With growing interest in immunotherapy for gliomas, improved methods are needed to identify patients who may respond. Advanced imaging techniques demonstrate promise as predictive tools for other treatments. We investigated the use of Dynamic Contrast Enhanced (DCE) MRI perfusion in predicting outcomes in patients with recurrent high grade glioma (rHGG) treated with immunotherapy. Sixteen patients with rHGG treated with pembrolizumab had DCE-MRI prior to and following the initiation of immunotherapy. Ktrans and plasma volume (Vp) were calculated using standard analysis procedures. Histogram ratios for baseline and initial follow up scans were correlated with progression-free survival (PFS) and overall survival (OS) using Kaplan-Meier curves and log-rank tests. Six patients received pembrolizumab alone, and 10 pembrolizumab with bevacizumab. Median age was 51.6 years (30-71); median recurrences prior to pembrolizumab was 3(1-5). From first immunotherapy treatment, median PFS was 2.5 months 95% CI (1.6,3.2) and median OS was 6.4 months 95% CI (3.4,12.2). One patient remains on treatment 17 months from initiation. Median time between scans was 1.8 months. The first scan after treatment initiation demonstrated no significant change from baseline mean rKtrans (12.43 to 11.16, p=0.73) or mean rVp (3.72 to 3.42, p=0.51). Using median rVp and rKtrans as cut offs, baseline rVp and rKtrans were not associated with PFS (2.7 vs 2.3 months, p= 0.17; 2.0 vs 2.6, p=0.12, respectively). Baseline rVp was not associated with OS, but baseline rKtrans was (5.1 vs 9.6 months, p= 0.05). In this small group of patients, outcomes were poor with the exception of one patient. Although perfusion parameters may be affected by bevacizumab, our results suggest baseline rKtrans may correlate with OS. Further investigation in a larger cohort is necessary to examine potential predictive value of DCE-MRI in OS and PFS in patients treated with immunotherapy with or without bevacizumab.
P2.01-041 Pemetrexed plus Platinum Chemotherapy with or Without Immuno Responses of Bevacizumab plus Cisplatin for the Non-Squamous Non-Small-Cell Lung Cancer Patients with Malignant Pleural Effusions Therapy in Non-Squamous NSCLC: Descriptive Safety Analysis
Authors: X. Li, J. Li
Journal: Journal of Thoracic Oncology (2017)
P3.16-039 Right Upper Lobectomy with SVC Reconstruction after Induction Chemoradiotherapy for a Patient with Bulky N2 NSCLC
Authors: H. Ichimura, T. Kawamura, K. Nakaoka, K. Kobayashi, M. Taguchi, T. Nawa, N. Kobayashi, S. Kikuchi, Y. Goto, M. Onizuka, Y. Sato, A. Sakata, M. Noguchi
Journal: Journal of Thoracic Oncology (2017)
EXTH-05. miR-34a INHIBITS GLIOBLASTOMA CELL PROLIFERATION AND SENSITIZES TO TEMOZOLOMIDE
Authors: Muhammad Babar Khan, Rosamaria Ruggieri, Nhan Tran, Jann Sarkaria, Marc Symons
Journal: Neuro-Oncology (2017)

Glioblastoma (GBM) is the most common primary brain tumor with a median survival of 14.5 months, despite maximal therapy consisting of surgical resection, radiation and temozolomide (TMZ). Genetic profiling has shown an average of three driver mutations localized to the p53, Rb and receptor tyrosine kinase networks, to be responsible for selective growth advantage of GBM. However, single cells from the same tumor often have different combinations of these driver mutations. This intra-tumoral heterogeneity is a major cause of treatment failure and disease recurrence. microRNA-34a (miR-34a) modulates the expression of multiple genes in all three deregulated GBM networks and therefore has the potential to counteract intra-tumor heterogeneity, thereby optimizing treatment. Transfection of miR-34a as monotherapy significantly reduced proliferation in multiple established GBM cell lines (A172, LN229, T98G and U251) and three primary patient-derived cell cultures (GBM6, GBM118 and GBM 126). The latter cultures were respectively characterized as classical, mesenchymal and proneural, based on mRNA expression analysis. In our in vitro experiments and the literature, T98G and U251 cell lines are resistant to TMZ, while A172 and LN229 are sensitive. miR-34a sensitized TMZ resistant, TMZ sensitive and primary cell cultures to TMZ. As an in vitro model of TMZ resistance, we cultured cells in TMZ for two weeks and created two stable TMZ resistant lines from A172 and LN229 which could be sensitized to TMZ after miR-34a treatment. Mechanistic studies indicate that miR-34a synergizes with TMZ due, in part, to direct inhibition of Bcl2 protein expression by miR-34a. Efforts also are ongoing to deliver miR-34a to orthotopic tumors using different types of nanoparticles. In conclusion, miR-34a is a promising novel therapeutic that inhibits proliferation and synergizes with TMZ in multiple GBM established cell lines and primary cultures.
Vigilância da listeriose humana na França, 2001-2003
Authors: V Goulet, C Jacquet, P Martin, V Vaillant, E Laurent, H de Valk
Journal: Eurosurveillance (2006)

A declaracao obligatoria da listeriose foi iniciada na Franca em 1999. A vigilância reforcada da saude publica, a caracterizacao molecular rotinaria dos surtos de L. monocytogenes, o seguimento epidemiologico dos casos e a colecao de amostras de alimentos, melhoraram a sensibilidade da deteccao dos surtos e a resposta. A incidencia da listeriose tem diminuando de 4,5 casos/milhao em 1999-2000 a 3,5 casos/ milhao aproximadamente durante o periodo 2001-2003. As caracteristicas clinicas, demograficas e microbiologicas da listeriose na Franca foram estaveis nesse periodo. As infeccoes materno-neonatais representaram 24% de todos os casos. O serotipo 4b estava presente em 49% dos casos e em 60% das agrupacoes. A incidencia da listeriose na Franca tem baixado e agora e inferior a alguns paises europeos.
NIMG-29. RADIOMIC ANALYSIS ON APPARENT DIFFUSION COEFFICIENT (ADC) MAPS PREDICTS PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (PDGFRA) GENE AMPLIFICATION FOR NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS
Authors: Stefania Maraka, Aikaterini Kotrotsou, Srishti Abrol, Ahmed Hassan, Nabil Elshafeey, Olga Starostina, Kristin Alfaro-Munoz, Rivka Colen, John de Groot
Journal: Neuro-Oncology (2017)

PDGFRA, an important therapeutic target, is the second most frequent mutated tyrosine kinase receptor in glioblastoma with amplification being the most common alteration. Radiogenomics is a novel field that correlates genetic alterations with imaging phenotypes. We sought to investigate the predictive power of radiomic analysis to successfully identify PDGFRA amplification status using ADC maps of treatment-naïve glioblastoma. We identified 28 treatment-naïve glioblastoma from the University of Texas MD Anderson Cancer Center database whom had gene expression profiles; 11 PDGFRA amplified, 17 not amplified. Baseline B0-DWI and ADC maps were processed and analyzed using 3D Slicer software 4.3.1. Regions of interests (ROIs) were selected on the tumors most restricted diffusion areas on every slice, and final segmented images were reviewed by a board-certified radiologist. Following tumor segmentation, radiomic analysis was performed on MATLAB environment, and a total of 310 rotation invariant radiomic features, which measure tumor heterogeneity, were extracted (intensity-level histogram and grey level co-occurrence matrix). An advanced feature selection method based on Minimum Redundancy Maximum Relevance (MRMR) was used to analyze the feature set and extract core features. Selected features were used to build a Support Vector Machine (SVM) model for prediction of PDGFRA amplification status. To evaluate the robustness of the estimates made with the SVM models, leave-one-out cross-validation was performed on the patient set. Thirty features were identified by the MRMR feature selection method and subsequently used to build the SVM model. The average overall prediction accuracy was 100% (95% CI: 87.66% - 100%), sensitivity 100% and specificity 100% (P<0.0001). The identification of PDGFRA amplification status can be reliably ascertained via the use of radiomic analysis. This study suggests that radiomics may identify a subgroup of glioblastoma tumors with specific genomic features and who may have a favorable response to PDGFRA targeted therapies.
P3.01-028 Efficacy of Osimertinib for Brain Metastasis in Advanced NSCLC: Data from Single Center in ASTRIS Trial
Authors: J.H. Kim, H.R. Kim, M.H. Hong, I.Y. Bang, R. Kim, H.W. Jung, H.J. Cho, H. Kim, H. Kim, B.C. Cho
Journal: Journal of Thoracic Oncology (2017)